ACVR2A

(redirected from ACTRII)

ACVR2A

A gene on chromosome 2q22.3 that encodes activin receptor type IIA, a receptor that forms a complex with other type-I and two type-II  transmembrane serine/threonine kinase receptors for activin, a dimeric growth and differentiating factor belonging to the TGF-beta superfamily of structurally related signalling proteins. Type-I receptors are essential for signalling; type-II receptors are required for binding ligands and expression of type-I receptors. After activin binding, type-I receptors phosphorylate cytoplasmic SMAD transcription factors, which then translocate to the nucleus and interact directly with DNA or in complex with other transcription factors, playing roles in cell differentiation, growth arrest and apoptosis.
References in periodicals archive ?
Both signal through the activin type II receptors (ActRII and ActRIIB).
Ligand-binding assays of COS cells that were transfected with the receptor revealed binding of MSTN to ActRIIB, and, to a lesser extent, to ActRIIA (Lee and McPherron, 2001), and binding of activin A to ActRII (Donaldson et al., 1992).
Injection of the antibodies to MSTN-mutant mice induced enhanced muscular hypertrophy, confirming a beneficial effect on muscle growth beyond MSTN inhibition alone through blockade of ActRII ligands (Lach-Trifilieff et al., 2014).
(2013) are the only two publications available in fish that show the potential application of soluble ActRII as an effective enhancer of cultured fish growth.
Earlier studies in mammals, in which direct binding assays of soluble ActRII and ActRIIB to radiolabeled activins and inhibins were tested, revealed that both receptors bind activin A with high affinity (del Re et al., 2004).
Activin binds to the activin type II receptors (ActRII), transphosphorylates type I receptors (activin receptor-like kinases, ALKs) (1-7) and forms the ActRII-IB/(ALK) 4 complex.
Activin signaling is blocked in cancer cells due to the complex formed by Cripto-1, activin, and activin receptor type II (ActRII).